Mihaela Horumbă
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Mihaela Horumbă has a total of 19 co-authors. Here are the top co-authors by number of shared publications:
G. Cristea
3 shared publicationsV. Vintila
3 shared publicationsA. Vintila
2 shared publicationsC. Tudorica
2 shared publicationsA.M. Vintila
Carol Davila Univ Med & Pharm, Coltea Clin Hosp, Bucharest, Romania
1 shared publicationAlberto Larghi
Digestive Endoscopy Unit, Fondazione Policlinico Universitario A. Gemelli, IRCCS, Rome, Italy
1 shared publication
Latest Publications
- 29 January 2020
- Published by Wiley in Digestive Endoscopy
- Vol. 32 (7) , 1031-1041
Interventional endoscopic ultrasound for pancreatic neuroendocrine neoplasms
The proximity of the endoscopic ultrasound (EUS) transducer to the pancreas and the possibility to place needles or other accessories into a target located adjacent to the wall of the GI tract have encouraged researchers to develop various EUS‐guided local treatments directed towards pancreatic neuroendocrine neoplasms (PanNENs). The use of pre‐operative EUS‐guided tattooing or fiducial marker placement to facilitate intraoperative tumor localization has proven effective in reducing operative time of laparoscopic surgeries. To reduce the mortality and morbidity rates of surgical resection, which is presently the mainstay treatment of PanNENs. EUS‐guided loco‐regional treatments, such as injection of alcohol and radiofrequency ablation have been proposed and results are hitherto promising. The present paper summarizes currently available data in the field of EUS‐guided interventions to pancreatic neuroendocrine tumors, as well as possible future applications.
- 29 January 2020
- Published by Wiley in Digestive Endoscopy
- Vol. 32 (7) , 1031-1041
Interventional endoscopic ultrasound for pancreatic neuroendocrine neoplasms
The proximity of the endoscopic ultrasound (EUS) transducer to the pancreas and the possibility to place needles or other accessories into a target located adjacent to the wall of the GI tract have encouraged researchers to develop various EUS‐guided local treatments directed towards pancreatic neuroendocrine neoplasms (PanNENs). The use of pre‐operative EUS‐guided tattooing or fiducial marker placement to facilitate intraoperative tumor localization has proven effective in reducing operative time of laparoscopic surgeries. To reduce the mortality and morbidity rates of surgical resection, which is presently the mainstay treatment of PanNENs. EUS‐guided loco‐regional treatments, such as injection of alcohol and radiofrequency ablation have been proposed and results are hitherto promising. The present paper summarizes currently available data in the field of EUS‐guided interventions to pancreatic neuroendocrine tumors, as well as possible future applications.
- 1 November 2019
- Published by Elsevier in Gastroenterology
- Vol. 157 (5) , 1203-1204
Currant Jelly-Like Clot-Induced Acute Pancreatitis
- 1 November 2019
- Published by Elsevier in Gastroenterology
- Vol. 157 (5) , 1203-1204
Currant Jelly-Like Clot-Induced Acute Pancreatitis
- 1 July 2019
- Published by Wolters Kluwer Health in Journal Of Hypertension
- Vol. 37, e192-E192
HEART RATE VARIABILITY IN A COHORT OF HYPERTENSIVE PATIENTS - A CLOSER LOOK AT RMSSD
Heart rate variability (HRV) is a measure of the autonomic regulation of the heart and is predictive for sudden cardiac death. rMSSD is an HRV parameter equal to the square root of the sum of all differences between successive R-R intervals and is indicative of parasympathetic activity. A retrospective study was performed on 69 hypertensive patients admitted to our clinic during a two year period. Data collected included patient demographics, history, comorbidities and treatment; moreover, laboratory assays, echocardiography and 24-Hour Holter monitoring information were made available for all patients. Patients in whom laboratory assays or echocardiographic data were unavailable and those with very low quality of the 24-hour electrocardiographic monitoring were excluded. Data analysis was performed using IBM SPSS, version 20 in order to obtain descriptive and inferential statistics. Out of the 69 patients, 68.10% were women, while 31.90% were men, with a mean age of 68.92 ± 9.91 years. All patients had arterial hypertension either grade 2 (27.50%) or grade 3 (72.50%) and underwent treatment with either ACEi/ARB, CCB, diuretic or a combination thereof. Most patients (77.20%) had left atrial enlargement with a mean volume of 73.32 ± 33.19 ml, though only 29% of patients had been previously diagnosed with atrial fibrillation. rMSSD (50.18 ± 33.30) correlated with age (p < 0.001), left atrial volume (p = 0.001), lateral wall MAPSE (13.14 ± 2.64 mm, p = 0.006), hemoglobin levels (13.17 ± 2.06 g/dl, p = 0.016) and mitral regurgitation severity (p < 0.01). The current study shows a high rMSSD in hypertensive patients in spite of antihypertensive treatment. Furthermore, since left atrial enlargement and age are both risk factors for atrial fibrillation, rMSSD may also be a sign that patients are prone to develop atrial fibrillation.
- 1 July 2019
- Published by Wolters Kluwer Health in Journal Of Hypertension
- Vol. 37, e192-E192
HEART RATE VARIABILITY IN A COHORT OF HYPERTENSIVE PATIENTS - A CLOSER LOOK AT RMSSD
Heart rate variability (HRV) is a measure of the autonomic regulation of the heart and is predictive for sudden cardiac death. rMSSD is an HRV parameter equal to the square root of the sum of all differences between successive R-R intervals and is indicative of parasympathetic activity. A retrospective study was performed on 69 hypertensive patients admitted to our clinic during a two year period. Data collected included patient demographics, history, comorbidities and treatment; moreover, laboratory assays, echocardiography and 24-Hour Holter monitoring information were made available for all patients. Patients in whom laboratory assays or echocardiographic data were unavailable and those with very low quality of the 24-hour electrocardiographic monitoring were excluded. Data analysis was performed using IBM SPSS, version 20 in order to obtain descriptive and inferential statistics. Out of the 69 patients, 68.10% were women, while 31.90% were men, with a mean age of 68.92 ± 9.91 years. All patients had arterial hypertension either grade 2 (27.50%) or grade 3 (72.50%) and underwent treatment with either ACEi/ARB, CCB, diuretic or a combination thereof. Most patients (77.20%) had left atrial enlargement with a mean volume of 73.32 ± 33.19 ml, though only 29% of patients had been previously diagnosed with atrial fibrillation. rMSSD (50.18 ± 33.30) correlated with age (p < 0.001), left atrial volume (p = 0.001), lateral wall MAPSE (13.14 ± 2.64 mm, p = 0.006), hemoglobin levels (13.17 ± 2.06 g/dl, p = 0.016) and mitral regurgitation severity (p < 0.01). The current study shows a high rMSSD in hypertensive patients in spite of antihypertensive treatment. Furthermore, since left atrial enlargement and age are both risk factors for atrial fibrillation, rMSSD may also be a sign that patients are prone to develop atrial fibrillation.
- 1 June 2018
- Published by Wolters Kluwer Health in Journal Of Hypertension
- Vol. 36 (Supplement) , e138-E138
DIABETES AND DYSLIPIDEMIA CONTROL IN A POPULATION OF HYPERTENSIVE PATIENTS WITH TYPE 2 DIABETES MELLITUS
Both diabetes and dyslipidemia are pervasive and treatable cardiovascular risk factors that combined with arterial hypertension increase the probability of ischemic cardiac disease. According to the 2016 ESC Dyslipidemia Guideline, type 2 diabetes mellitus patients associating cardiovascular disease or chronic kidney disease and those over the age of 40 with one or more additional CVD risk factors or target organ damage should maintain an LDL value of under 70 mg/dl. Moreover, a HbA1c of under 7% should be achieved with antidiabetic treatment in order to prevent chronic diabetic complications. Our aim was to evaluate whether LDL-cholesterol and glycated hemoglobin targets were achieved among patients with concurrent hypertension and type 2 diabetes mellitus. A retrospective study was performed on patients admitted to our clinic between January 2016 and December 2017. A total of 1078 in-patients with concurrent hypertension and type 2 diabetes mellitus - 640 females and 438 males with a mean age of 69,03 +/- 9.88 years - were included in the analysis. Laboratory workup was performed according to standards of care, including lipid profile and HbA1c. All patients were over the age of 40, with type 2 diabetes and at least one additional CVD risk factor (arterial hypertension), thus the LDL-target was considered 70 mg/dl. Over 50% of patients had severe hypertension (systolic values over 180 mmHg). The distribution was: 57% of patients had grade 3 hypertension, 12% grade 2 hypertension and 31% grade 1 hypertension. The mean serum LDL-cholesterol was 91,35 +/- 38,12 mg/dl, with a median of 87 mg/dl. Only 31.6% of patients achieved the 70 mg/dl target. Furthermore, mean HbA1c was 7,29% +/- 1,5% with a median of 6,9%. Only 46,5% reached the desired threshold of 7%. Diabetes and dyslipidemia control is suboptimal in our population. Moreover, lifestyle and diet changes should be encouraged in the at-risk population so as to prevent development of complications. Efforts should be made in order to better achieve targets recommended by current guidelines.
- 1 June 2018
- Published by Wolters Kluwer Health in Journal Of Hypertension
- Vol. 36 (Supplement) , e138-E138
DIABETES AND DYSLIPIDEMIA CONTROL IN A POPULATION OF HYPERTENSIVE PATIENTS WITH TYPE 2 DIABETES MELLITUS
Both diabetes and dyslipidemia are pervasive and treatable cardiovascular risk factors that combined with arterial hypertension increase the probability of ischemic cardiac disease. According to the 2016 ESC Dyslipidemia Guideline, type 2 diabetes mellitus patients associating cardiovascular disease or chronic kidney disease and those over the age of 40 with one or more additional CVD risk factors or target organ damage should maintain an LDL value of under 70 mg/dl. Moreover, a HbA1c of under 7% should be achieved with antidiabetic treatment in order to prevent chronic diabetic complications. Our aim was to evaluate whether LDL-cholesterol and glycated hemoglobin targets were achieved among patients with concurrent hypertension and type 2 diabetes mellitus. A retrospective study was performed on patients admitted to our clinic between January 2016 and December 2017. A total of 1078 in-patients with concurrent hypertension and type 2 diabetes mellitus - 640 females and 438 males with a mean age of 69,03 +/- 9.88 years - were included in the analysis. Laboratory workup was performed according to standards of care, including lipid profile and HbA1c. All patients were over the age of 40, with type 2 diabetes and at least one additional CVD risk factor (arterial hypertension), thus the LDL-target was considered 70 mg/dl. Over 50% of patients had severe hypertension (systolic values over 180 mmHg). The distribution was: 57% of patients had grade 3 hypertension, 12% grade 2 hypertension and 31% grade 1 hypertension. The mean serum LDL-cholesterol was 91,35 +/- 38,12 mg/dl, with a median of 87 mg/dl. Only 31.6% of patients achieved the 70 mg/dl target. Furthermore, mean HbA1c was 7,29% +/- 1,5% with a median of 6,9%. Only 46,5% reached the desired threshold of 7%. Diabetes and dyslipidemia control is suboptimal in our population. Moreover, lifestyle and diet changes should be encouraged in the at-risk population so as to prevent development of complications. Efforts should be made in order to better achieve targets recommended by current guidelines.
- 1 June 2018
- Published by Wolters Kluwer Health in Journal Of Hypertension
- Vol. 36 (Supplement) , e256-E256
SERUM LDL AND GLYCEMIC CONTROL IN PATIENTS WITH CONCURRENT ATRIAL FIBRILLATION, ARTERIAL HYPERTENSION AND TYPE 2 DIABETES MELLITUS
Atrial fibrillation (AF) is one of the leading causes of stroke, heart failure, sudden death and cardiovascular mortality in the world. Diabetes and dyslipidemia are other risk factors for stroke and often coexist with AF. The aim of our study was to assess control of LDL-cholesterol and glycated hemoglobin (HbA1c) in AF patients at very high risk due to concurrent hypertension and type 2 diabetes mellitus. We performed a retrospective analysis on patients admitted over a two year interval (January 2016 to December 2017). Our study included patients with both arterial hypertension and type 2 diabetes mellitus - a total of 438 men (40,57%) and 640 women (59,42%) (n = 1078), out of which 317 (29,40%) also exhibited AF. Serum cholesterol, glycemia and HbA1c were analyzed. As all patients were over the age of 40, with diabetes mellitus and at least one additional cardiovascular risk factor (arterial hypertension), the estimated cardiovascular risk was very high. Thus, HbA1c and LDL-cholesterol targets were below 7% and 70 mg/dl, respectively. The mean age of enrolled patients was 69,03 ± 9,88 years, with AF patients being older (73,1 ± 8,7) than those without AF (67,3 ± 9,9), p < 0.001. Patients with atrial fibrillation had better glycemic control than those without AF, with mean glycemia 133,1 ± 60,4 mg/dl (p = 0.008) and HbA1c values of 6,8 ± 1,6% (p < 0.001) as opposed to 145,6 ± 74,8 mg/dl and 7,4 ± 1,7%. Two thirds of AF patients (66.1%) had HbA1c below 7%. LDL-cholesterol values were lower in AF patients: mean LDL 67,2 ± 27,1 mg/dl versus 81,0 ± 30,2 mg/dl, p < 0.001. Still, only 38.4% of AF patients had LDL values below target. Diabetes and hypertension are risk factors that increase the likelihood of stroke. Dyslipidemia leads to atherosclerotic plaque formation, while atrial fibrillation, even under anticoagulant treatment, may produce emboli that disrupt cerebral blood flow. As a consequence, cardiovascular risk factors should be even more strictly corrected in patients with concurrent AF. However, as the analysis performed on patients presenting to our clinic suggests, though diabetes and dyslipidemia control are better in AF patients than in the general population, improvement is needed in order to decrease cardiovascular risk.
- 1 June 2018
- Published by Wolters Kluwer Health in Journal Of Hypertension
- Vol. 36 (Supplement) , e256-E256
SERUM LDL AND GLYCEMIC CONTROL IN PATIENTS WITH CONCURRENT ATRIAL FIBRILLATION, ARTERIAL HYPERTENSION AND TYPE 2 DIABETES MELLITUS
Atrial fibrillation (AF) is one of the leading causes of stroke, heart failure, sudden death and cardiovascular mortality in the world. Diabetes and dyslipidemia are other risk factors for stroke and often coexist with AF. The aim of our study was to assess control of LDL-cholesterol and glycated hemoglobin (HbA1c) in AF patients at very high risk due to concurrent hypertension and type 2 diabetes mellitus. We performed a retrospective analysis on patients admitted over a two year interval (January 2016 to December 2017). Our study included patients with both arterial hypertension and type 2 diabetes mellitus - a total of 438 men (40,57%) and 640 women (59,42%) (n = 1078), out of which 317 (29,40%) also exhibited AF. Serum cholesterol, glycemia and HbA1c were analyzed. As all patients were over the age of 40, with diabetes mellitus and at least one additional cardiovascular risk factor (arterial hypertension), the estimated cardiovascular risk was very high. Thus, HbA1c and LDL-cholesterol targets were below 7% and 70 mg/dl, respectively. The mean age of enrolled patients was 69,03 ± 9,88 years, with AF patients being older (73,1 ± 8,7) than those without AF (67,3 ± 9,9), p < 0.001. Patients with atrial fibrillation had better glycemic control than those without AF, with mean glycemia 133,1 ± 60,4 mg/dl (p = 0.008) and HbA1c values of 6,8 ± 1,6% (p < 0.001) as opposed to 145,6 ± 74,8 mg/dl and 7,4 ± 1,7%. Two thirds of AF patients (66.1%) had HbA1c below 7%. LDL-cholesterol values were lower in AF patients: mean LDL 67,2 ± 27,1 mg/dl versus 81,0 ± 30,2 mg/dl, p < 0.001. Still, only 38.4% of AF patients had LDL values below target. Diabetes and hypertension are risk factors that increase the likelihood of stroke. Dyslipidemia leads to atherosclerotic plaque formation, while atrial fibrillation, even under anticoagulant treatment, may produce emboli that disrupt cerebral blood flow. As a consequence, cardiovascular risk factors should be even more strictly corrected in patients with concurrent AF. However, as the analysis performed on patients presenting to our clinic suggests, though diabetes and dyslipidemia control are better in AF patients than in the general population, improvement is needed in order to decrease cardiovascular risk.
- 2 February 2018
- Published by Springer Nature
- p. 455-473
Right Heart Involvement in Haematologic Disorders
- 2 February 2018
- Published by Springer Nature
- p. 455-473
Right Heart Involvement in Haematologic Disorders